New York State Teachers Retirement System Has $30.43 Million Position in IQVIA Holdings Inc. (NYSE:IQV)

New York State Teachers Retirement System trimmed its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 7.2% in the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 154,869 shares of the medical research company's stock after selling 12,071 shares during the quarter. New York State Teachers Retirement System owned 0.09% of IQVIA worth $30,433,000 as of its most recent filing with the SEC.

Several other hedge funds have also recently bought and sold shares of the stock. Capital Performance Advisors LLP acquired a new stake in shares of IQVIA during the third quarter worth $27,000. Synergy Asset Management LLC bought a new position in shares of IQVIA during the fourth quarter worth about $33,000. Avior Wealth Management LLC raised its position in IQVIA by 117.6% in the 3rd quarter. Avior Wealth Management LLC now owns 161 shares of the medical research company's stock valued at $38,000 after buying an additional 87 shares during the last quarter. Assetmark Inc. lifted its stake in IQVIA by 612.5% in the 3rd quarter. Assetmark Inc. now owns 228 shares of the medical research company's stock valued at $54,000 after acquiring an additional 196 shares in the last quarter. Finally, Concord Wealth Partners acquired a new position in IQVIA during the 3rd quarter worth approximately $57,000. 89.62% of the stock is currently owned by institutional investors and hedge funds.

IQVIA Stock Performance

Shares of NYSE:IQV traded up $3.39 during trading on Wednesday, reaching $196.54. 1,700,843 shares of the stock were exchanged, compared to its average volume of 1,411,159. The firm has a market cap of $34.61 billion, a PE ratio of 26.21, a PEG ratio of 1.98 and a beta of 1.48. The company has a current ratio of 0.84, a quick ratio of 0.84 and a debt-to-equity ratio of 2.12. IQVIA Holdings Inc. has a 12 month low of $187.62 and a 12 month high of $261.73. The stock has a 50-day moving average price of $199.95 and a 200-day moving average price of $217.09.

IQVIA (NYSE:IQV - Get Free Report) last released its quarterly earnings results on Thursday, February 6th. The medical research company reported $2.90 EPS for the quarter, missing analysts' consensus estimates of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. Research analysts expect that IQVIA Holdings Inc. will post 10.86 EPS for the current fiscal year.

Insider Activity at IQVIA

In related news, Director John G. Danhakl acquired 1,275 shares of the company's stock in a transaction on Tuesday, December 3rd. The stock was purchased at an average cost of $200.58 per share, with a total value of $255,739.50. Following the acquisition, the director now directly owns 1,275 shares of the company's stock, valued at approximately $255,739.50. The trade was a ∞ increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 1.60% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

A number of research firms have recently issued reports on IQV. William Blair reiterated an "outperform" rating on shares of IQVIA in a report on Wednesday, December 11th. Stifel Nicolaus lowered their price target on shares of IQVIA from $273.00 to $261.00 and set a "buy" rating on the stock in a research note on Friday, February 7th. Barclays reduced their price objective on shares of IQVIA from $255.00 to $235.00 and set an "overweight" rating for the company in a research note on Monday, February 3rd. JPMorgan Chase & Co. decreased their price objective on IQVIA from $240.00 to $232.00 and set an "overweight" rating for the company in a report on Tuesday. Finally, BTIG Research lowered IQVIA from a "buy" rating to a "neutral" rating in a report on Monday, February 3rd. Four research analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $251.22.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.